Literature DB >> 28504207

A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder.

Kentaro Inamura1, Maki Kobayashi2, Hiroko Nagano2, Yoshiya Sugiura2, Masahiro Ogawa3, Hitoshi Masuda3, Junji Yonese3, Yuichi Ishikawa2.   

Abstract

Here, we report an inflammatory myofibroblastic tumor (IMT) of the urinary bladder with a novel HNRNPA1-ALK fusion. To the best of our knowledge, this is the first case of a tumor with HNRNPA1-ALK fusion. A 42-year-old Japanese man underwent total cystectomy because of an invasive urinary bladder tumor. Grossly, the tumor had invaded the peribladder fat tissue. Histologically, it comprised spindle neoplastic cells with intermingled inflammatory cells. Immunohistochemically, it was positive for ALK, SMA, desmin, cytokeratin, and vimentin, consistent with the immunohistochemical characteristics of IMTs. Fluorescence in situ hybridization demonstrated an ALK split, and the presence of HNRNPA1-ALK was revealed by RNA sequencing. We identified a novel transcript fusion of exon 2 of HNRNPA1 and exon 18 of ALK, resulting in ALK protein overexpression. These findings provide useful information on the biology and tumorigenesis of IMTs, thus facilitating the development of molecular-targeted therapeutics.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALK; Chromosomal rearrangement; HNRNPA1–ALK fusion; Inflammatory myofibroblastic tumor; Spindle cell tumor; Urinary bladder tumor; hnRNP

Mesh:

Substances:

Year:  2017        PMID: 28504207     DOI: 10.1016/j.humpath.2017.04.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.

Authors:  Fernando Vargas-Madueno; Edwin Gould; Raul Valor; Nhu Ngo; Linsheng Zhang; Miguel A Villalona-Calero
Journal:  Oncologist       Date:  2018-05-08

2.  Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile.

Authors:  Steven D Billings; Jennifer S Ko; Josephine K Dermawan; Elizabeth M Azzato; John R Goldblum; Brian P Rubin
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

3.  Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.

Authors:  Paolo Bonvini; Elisabetta Rossi; Angelica Zin; Mariangela Manicone; Riccardo Vidotto; Antonella Facchinetti; Lucia Tombolan; Maria Carmen Affinita; Luisa Santoro; Rita Zamarchi; Gianni Bisogno
Journal:  Front Pediatr       Date:  2021-04-29       Impact factor: 3.418

4.  The Clinical and Radiological Characteristics of Inflammatory Myofibroblastic Tumor Occurring at Unusual Sites.

Authors:  Xuewei Zeng; Huayi Huang; Jun Li; Jiayou Peng; Jiaxiong Zhang
Journal:  Biomed Res Int       Date:  2018-05-14       Impact factor: 3.411

Review 5.  Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.

Authors:  Hao Huang
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

6.  Inflammatory Myofibroblastic Tumor of the Urinary Bladder: An 11-Year Retrospective Study From a Single Center.

Authors:  Can Chen; Mengjun Huang; Haiqing He; Shuiqing Wu; Mingke Liu; Jun He; Hongjing Zang; Ran Xu
Journal:  Front Med (Lausanne)       Date:  2022-03-03

Review 7.  Recurrent uterine tumors resembling ovarian sex-cord tumors with the growth regulation by estrogen in breast cancer 1-nuclear receptor coactivator 2 fusion gene: a case report and literature review.

Authors:  Bin Chang; Qianming Bai; Lin Liang; Huijuan Ge; Qianlan Yao
Journal:  Diagn Pathol       Date:  2020-09-14       Impact factor: 2.644

8.  Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.

Authors:  Tien-Chi Hou; Pao-Shu Wu; Wen-Yu Huang; Yi-Ting Yang; Kien Thiam Tan; Shih-Hua Liu; Yu-Jen Chen; Shu-Jen Chen; Ying-Wen Su
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.